H. pylori May Inflame Coronary Arteries, But Routine Screening Falls Short

A bacterium best known for causing stomach ulcers has been quietly accumulating a cardiovascular rap sheet. Helicobacter pylori, which colonizes roughly 43% of the global population according to recent systematic reviews, has long been suspected as a contributor to atherosclerosis and coronary heart disease (CHD). A doctoral thesis from Karolinska Institutet, authored by M Sundqvist and published in May 2026, is one of the most comprehensive attempts yet to settle the question, drawing on laboratory experiments, Swedish population data, and a cluster-randomized clinical trial across 35 hospitals.

CagA Protein Triggers Inflammation and Calcification in Coronary Artery Cells

The thesis opens at the cellular level. In laboratory experiments using human coronary artery smooth muscle cells (CASMCs), Sundqvist's team exposed the cells to CagA, a virulence protein produced by the most aggressive strains of H. pylori. The result was a clear pro-inflammatory and pro-calcific response: the cells shifted toward states associated with arterial stiffening and plaque formation. This matters because CagA-positive H. pylori strains have been implicated in mechanisms like chronic inflammation, endothelial damage, dyslipidemia, and hyperhomocysteinemia that are already established drivers of atherosclerosis. The lab finding gave biological plausibility to the epidemiological suspicion.

Earlier meta-analyses had pointed in the same direction. A 2022 updated meta-analysis in Frontiers in Cardiovascular Medicine concluded that H. pylori infection significantly raises the odds of CHD, with the association especially pronounced for CagA-positive serology. The Sundqvist thesis was designed partly to test whether that signal holds up in real-world Swedish data and whether doing something about it in hospitals actually helps patients.

H. pylori's Effect on MI Incidence Disappears After Adjustment, But Inflammation Persists

When Sundqvist turned to population data, the picture became more complicated. A nested case-control study drawn from the Northern Sweden Health and Disease cohort found that H. pylori seropositivity (46.5% in cases, 43.7% in controls) and CagA seropositivity (32.1% in cases, 30.6% in controls) were not significantly associated with incident myocardial infarction (MI) once standard cardiovascular risk factors were accounted for. In other words, the bacteria's apparent heart risk may largely be explained by the company it keeps: inflammation, metabolic disruption, and other confounders.

That said, a separate prospective cohort study in the thesis told a different story for patients who had already survived an MI. Among those patients, H. pylori infection, and CagA-positive strains in particular, was associated with meaningfully higher systemic inflammation as measured by C-reactive protein (CRP). Inflammatory markers including CRP also emerged as predictors of H. pylori status in this group. The implication is nuanced: H. pylori may not be a primary cause of first heart attacks, but it may sustain or worsen inflammatory burden in people who already have established coronary disease. A broad meta-analysis across 87 studies found H. pylori present in 56.7% of patients with vascular diseases, underlining how common this co-occurrence is.

The HELP-MI SWEDEHEART Trial: Routine Screening Did Not Cut Bleeding or Deaths

The most clinically direct component of the thesis was the HELP-MI SWEDEHEART trial, a cluster-randomized crossover study run across 35 Swedish hospitals. The core question was practical: if you routinely screen MI patients for H. pylori using a urea breath test and then eradicate the infection, do you reduce upper gastrointestinal bleeding (UGIB), which is a serious complication when MI patients are placed on antithrombotic therapy?

The answer, for unselected MI patients, was no. Routine screening did not significantly reduce UGIB, and it produced no meaningful improvement in cardiovascular outcomes or mortality. This is a sobering result for anyone hoping that a simple breath test and a course of antibiotics could become a standard part of post-MI care.

The mechanism driving the concern is real enough. H. pylori can induce platelet activation and aggregation, and it increases the vulnerability of the gastric lining to bleeding, which becomes dangerous when patients are taking aspirin, P2Y12 inhibitors, or anticoagulants after a heart attack. The issue is that applying screening to everyone, regardless of bleeding risk, dilutes any benefit.

Conflicting Evidence and the Limits of Serological Testing

The thesis is candid about its limitations, and the broader literature's. Existing data on H. pylori and CHD are conflicting, partly because of heterogeneous study designs and highly variable patient populations. The population-based case-control result rules out a large effect on incident MI, but the authors acknowledge that a small causal contribution cannot be definitively excluded. Serological testing, which detects past exposure rather than active infection, further complicates interpretation: a positive antibody result may reflect a cleared infection rather than an ongoing one, potentially misclassifying some participants. The study's European ancestry sample also limits generalizability to populations with different H. pylori strain distributions and baseline cardiovascular risk profiles.

The proposed biological pathways are also still being mapped. BMI may partially mediate any causal effect of H. pylori on CHD, which would mean that eradication could indirectly benefit heart patients through metabolic changes rather than through direct anti-inflammatory action. Vitamin B12 and folate deficiencies linked to chronic H. pylori infection have also been proposed as intermediary mechanisms, as has the bacterium's tendency to alter glucose and lipid metabolism.

Targeted Screening for High-Bleeding-Risk MI Patients as the Practical Path Forward

Despite the null result in the broad SWEDEHEART trial, the thesis does not conclude that H. pylori is irrelevant to cardiology. Instead, it reframes the question. Targeted H. pylori screening and eradication for MI patients who are at high risk of gastrointestinal bleeding, rather than everyone who shows up after a heart attack, is flagged as a clinically meaningful strategy. Patients who need long-term dual antiplatelet therapy or who have prior ulcer history would be the obvious candidates.

This is consistent with evidence from a large Taiwanese cohort study that found a trend toward lower CHD-associated mortality in younger patients who received H. pylori eradication therapy, suggesting that in the right population, treatment may carry real benefit. The Sundqvist thesis adds rigorous European data to that picture, sharpening the argument for risk-stratified, rather than universal, screening. What the field still lacks is a large trial powered specifically for that high-risk subgroup, with long enough follow-up to detect changes in cardiovascular outcomes. That study, the thesis implies, still needs to be done.